Fundz

F2G raised $100M in a debt financing round led by AMR Action Fund to complete late-stage development and seek regulatory approval for its novel oral antifungal therapy, olorofim.

PRIVATESep 13, 2024

Amount Raised

$100

Round Type

Pre-Seed

Biotechnology

Investors

Merifin CapitalBrace PharmaceuticalsMorningside VenturesBlue Owl Healthcare OpportunitiesForbionSofinnova PartnersAdvent Life SciencesNovo HoldingsICG Life SciencesAMR Action Fund

Description

F2G, a clinical-stage biopharmaceutical company based in Manchester, has secured $100M in funding to advance its development of olorofim, an antifungal treatment. The round was co-led by AMR Action Fund and ICG Life Sciences, with participation from several existing investors.

Who else raised in Biotechnology around the same time

Companies in the same sectors as F2G that raised within 45 days of this round, from Fundz verified event records.

  • Dash Bio raised $6.5M (Seed) on October 28, 2024.
  • MAIA Biotechnology raised $2.4M (Seed) on October 28, 2024.
  • Resalis Therapeutics raised an undisclosed amount on October 28, 2024.
  • Kivu Bioscience raised $92M (Series A) on October 28, 2024.
  • Earthodic raised $4M (Seed) on October 28, 2024.
  • Senseonics raised $16M on October 28, 2024.

Who to call at F2G, and when

A new round usually means F2G is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day F2G raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at F2G, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at F2G. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

F2G

Location

Lankro Way

About

F2G is a biotech company with operations in the UK, US, and Austria focused on the discovery and development of novel therapies to treat potentially life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides which selectively target a key enzyme in the de novo pyrimidine biosynthesis pathway. This is a completely different mechanism from that of the currently marketed antifungal agents and gives the orotomides fungicidal activity against a broad range of rare and resistant fungal mold infections.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment F2G raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsFrancesco M., Chief Executive Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for F2G's next move

See what Strategic adds

F2G raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.